Risk Stratification and Treatment Goals for Pulmonary Arterial Hypertension Risikostratifizierung und Behandlungsziele bei pulmonalarterieller Hypertonie
Olschewski H, Barnikel M, Pittrow D, Schwaiblmair M, Suleiman M, Yogeswaran A, Xanthouli P, Gieseke P, Douschan P, Kaemmerer-Suleiman AS, Krüger S, Sorichter S, John T, Ulrich S (2025)
Publication Type: Journal article, Review article
Publication year: 2025
Journal
Book Volume: 79
Pages Range: 751-761
Journal Issue: 10
DOI: 10.1055/a-2625-4844
Abstract
Risk stratification plays an important role in predicting outcomes and guiding treatment decisions of patients with pulmonary arterial hypertension (PAH). The three most important non-invasive predictive prognostic factors are the World Health Organization functional class, the 6-minute walk distance, and natriuretic peptides. These three are included in all currently validated risk stratification tools. However, due to limitations primarily related to the reduced specificity of PAH severity, these variables are not always sufficient to guide individual treatment decisions. Furthermore, with effective combination and new PAH therapies, markers associated with pulmonary vascular remodeling are expected to become increasingly relevant for guiding the treatment of patients with PAH. While achieving a low mortality risk, measured with a validated risk assessment tool, remains an important treatment goal, preliminary data suggest that invasive hemodynamics and cardiac imaging may provide additional value in guiding treatment decisions.
Authors with CRIS profile
Mathieu Suleiman
Department of Cardiac Surgery
Ann-Sophie Kaemmerer-Suleiman
Department of Cardiac Surgery
Involved external institutions
Charité - Universitätsmedizin Berlin
Germany (DE)
Klinikum der Universität München (LMU Klinikum)
Germany (DE)
Universitätsklinikum Carl Gustav Carus Dresden
Germany (DE)
Universitätsklinikum Augsburg
Germany (DE)
Justus-Liebig-Universität Gießen
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Medizinische Universität Graz
Austria (AT)
Universitätsklinikum Düsseldorf
Germany (DE)
Universitätsspital Zürich (USZ)
Switzerland (CH)
Germany (DE)
Klinikum der Universität München (LMU Klinikum)
Germany (DE)
Universitätsklinikum Carl Gustav Carus Dresden
Germany (DE)
Universitätsklinikum Augsburg
Germany (DE)
Justus-Liebig-Universität Gießen
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Medizinische Universität Graz
Austria (AT)
Universitätsklinikum Düsseldorf
Germany (DE)
Universitätsspital Zürich (USZ)
Switzerland (CH)
How to cite
APA:
Olschewski, H., Barnikel, M., Pittrow, D., Schwaiblmair, M., Suleiman, M., Yogeswaran, A.,... Ulrich, S. (2025). Risk Stratification and Treatment Goals for Pulmonary Arterial Hypertension Risikostratifizierung und Behandlungsziele bei pulmonalarterieller Hypertonie. Pneumologie, 79(10), 751-761. https://doi.org/10.1055/a-2625-4844
MLA:
Olschewski, Horst, et al. "Risk Stratification and Treatment Goals for Pulmonary Arterial Hypertension Risikostratifizierung und Behandlungsziele bei pulmonalarterieller Hypertonie." Pneumologie 79.10 (2025): 751-761.
BibTeX: Download